Abstract: The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus Pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.

Abstract: Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.

Abstract: A pharmaceutical composition comprising a LH antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier is useful for deferring the onset of menopause.

Abstract: The present invention provides novel compounds of Formula 1 or Formula 2 and compositions thereof, methods of their use, and methods of their manufacture, wherein X, Y, Z, W, R1, R2 and R3 are defined more fully in the description. These compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and a number of other diseases.

Abstract: An enzyme exhibiting polygalacturonase activity, which enzyme is immunologically reactive with an antibody raised against a purified polygalacturonase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be produced by recombinant DNA techniques and may be used for degradation of plant cell walls, for instance in the wine and juice production.

Abstract: The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib ##STR1## or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

Abstract: An immobilized enzyme preparation for use in an organic medium essentially devoid of free water is prepared using a fluidized bed. An enzyme-containing liquid medium is contacted with a particulate porous carrier which preferably has a particle size of 200-1000 .mu.m and a surface area of 20-1000 m.sup.2 /g, and volatile components of the liquid medium are removed to fix or adsorb the enzyme on the carrier. The carrier may have a hydrophilic surface and an amount of liquid medium is used to prevent agglomeration of the carrier. The enzyme can be adsorbed on a carrier having a hydrophobic surface, and the addition of a hygroscopic substance suppresses agglomeration of the carrier by absorbing excess liquid. The hygroscopic substance may be removed during the removal of volatile components.

Abstract: Guanidine and diaminonitroethene derivatives represented by the formula ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The se compounds are useful in the treatment of diseases of the central nervous system, cardiovascular system, pulmonary system, gastrointestinal system and endocrinologic system.

Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having pyranose oxidase activity. The invention also relates to nucleic acid constructs, vectors and host cells containing the nucleic acid sequences as well as recombinant methods for producing the polypeptides.

Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (I): ##STR1## wherein a, b, A, R.sup.1, L.sup.1, D, R.sup.3, R.sup.4, R.sup.2, L.sup.2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.

Abstract: Compounds of the general formula I ##STR1## compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are described.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: The present invention relates to novel affinity ligand-matrix conjugates comprising a ligand with the general formula (a) ##STR1## which ligand is attached to a support matrix in position (A), optionally through a spacer arm interposed between the matrix and ligand. The invention furthermore relates to these novel affinity ligand-matrix conjugates and the preparation and use thereof in the purification of proteinaceous materials such as e.g. immunoglobulins, insulins, Factor VII, or human Growth Hormone or analogues, derivatives and fragments thereof and precursors.

Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neuragenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: Disclosed are compounds of formula (I) ##STR1## wherein R1 is C.sub.1-8 -alkyl, C.sub.2-8 -alkenyl, C.sub.3-8 -cycloalkyl, C.sub.5-8 -cycloalkenyl, Q or aryl;R2 is C.sub.1-8 -alkyl, C.sub.2-8 -alkenyl, C.sub.3-8 -cycloalkyl, C.sub.5-8 -cycloalkenyl, aralkyl or COR3;R3 is C.sub.1-8 -alkyl, C.sub.2-8 -alkenyl, C.sub.3-8 -cycloalkyl, C.sub.5-8 -cycloalkenyl, w or aryl;R5, R6 and R7 are independently selected from amino-C.sub.1-6 -alkyl, hydroxy-C.sub.1-6 -alkyl, hydrogen, C.sub.1-6 -alkyl, aryl, aralkyl, aryloxy, aryloxy-C.sub.1-6 -alkyl, benzyl, halogen, hydroxy, mercapto, cyano, nitro, carboxy, carbamoyl, CONHC.sub.1-4 -alkyl, CON(C.sub.1-4 alkyl).sub.2, C.sub.1-4 -acyl, C.sub.1-4 -alkoxy, C.sub.1-4 -alkylthio, --SOC.sub.1-6 -alkyl, --SO.sub.2 C.sub.1-6 -alkyl, C.sub.1-4 -alkoxycarbonyl, C.sub.1-4 -alkanoyloxy, amino, optionally substituted mono- or di-C.sub.1-6 -alkylamino, acylamino, --NC.sub.1-4 -alkylCOC.sub.1-4 -alkyl, --SO3H, --SO2NH--C.sub.

Abstract: The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of formula (I) ##STR1## wherein (L).sub.n, Ar.sub.1, R.sub.1 and A are as defined in the application.

Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.